Skip to main content

Table 3 Univariate and multivariate analysis of the prognostic value of miR-25 and miR-142 in OS

From: Bevacizumab confers significant improvements in survival for ovarian cancer patients with low miR-25 expression and high miR-142 expression

Variables Number of patients Univariate analysis Multivariate analysis
HR (95%CI) P value HR (95%CI) P value
Age 380 1.036 (1.014–1.058) 0.001 1.033 (1.010–1.056) 0.004
Stage    0.003   0.012
 Early 51 1   1  
 Late 329 5.661 (1.792–17.885) 4.229 (1.324–13.515)
Grade    0.798   /
 Low 74 1   /  
 High 281 1.069 (0.644–1.774)   /  
 NA 25 /   /  
Debulking    0.002   0.074
 Optimal 290 1   1  
 Suboptimal 88 1.991 (1.299–3.050)   1.497 (0.962–2.328)  
 Inoperable 2 /    
Treatment    0.072   0.087
 Standard 181 1   1  
 Standard+Bevacizumab 199 0.692 (0.463–1.034)   0.702 (0.468–1.052)  
miR-25 expression    0.009   0.013
 Low 341 1   1  
 High 39 0.217 (0.069–0.687)   0.233 (0.073–0.738)  
miR-142 expression    0.052   0.091
 Low 99 1   1  
 High 281 1.648 (0.996–2.727)   1.547 (0.933–2.566)